Funders · Entity Annotation Prototype (beta)

2articles mentioning funders

2funder mentions

1distinct funders extracted

0%of mentions human-reviewed

Active filtersEntity: Optum Clinformatics ×

Optum Clinformatics

This funder is selected. Its supporting articles are shown below.

Optum Clinformatics2

Articles mentioning Optum Clinformatics

2 articles · page 1 of 1

Using real-world data to predict findings of an ongoing phase IV trial: glycemic control of semaglutide versus standard of care

bmjdrc · abstract · 2025-10-29 · 1 matching annotations

85.2%

ClinicalTrials.gov Optum Clinformatics semaglutide type-2 diabetes mellitus T2D metformin dipeptidyl peptidase-4 inhibitors

…ng A1C <7%. The study protocol was preregistered ( NCT05577728, ClinicalTrials.gov) before any etiologic analyses. Risk ratios and corresponding 9…

Using real-world data to predict findings of an ongoing phase IV trial: glycemic control of semaglutide versus standard of care

bmjdrc · full text · 2025-10-29 · 1 matching annotations

88.2%

Optum Clinformatics American Diabetes Association Medicare586 21st Century Cures Act clinicaltrials.gov US Food and Drug Administration semaglutide type two diabetes mellitus T2DM end-stage renal disease+4 more

…ability of this data is driven by lab provider partnerships for Optum Clinformatics. We use our inclusion criteria to balance the availability of l…

Browse funders

Optum Clinformatics

Articles mentioning Optum Clinformatics

Using real-world data to predict findings of an ongoing phase IV trial: glycemic control of semaglutide versus standard of care

Using real-world data to predict findings of an ongoing phase IV trial: glycemic control of semaglutide versus standard of care